Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| CYK0496-25 | 7 days | 25 µg | $1,200.00 |
Select product before adding to cart
|
||
| CYK0496-50 | 7 days | 50 µg | $1,980.00 | |||
| CYK0496-100 | 7 days | 100 µg | $2,400.00 |
Product Overview | |
| Name | proBNP Human |
|---|---|
| Description | |
| Pro B-type Natriuretic Protein Human Recombinant | |
| Accession (Primary) | P16860 |
| Synonyms | |
| Calcitonin, Calca, Calc, CCALCI. | |
| Introduction | |
| Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. Levels of unprocessed procalcitonin rise significantly after bacterial infection, trauma or shock. | |
| Source | |
| Escherichia Coli. | |
| Physical Appearance | |
| Filtered White lyophilized (freeze-dried) powder. | |
| Formulation | |
| Procalcitonin was filtered (0.4 µm) and lyophilized in 20mM TRIS and 50mM NaCl, pH 7.2. | |
| Stability | |
| Store lyophilized protein at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C. | |
| Purity | |
| Greater than 90.0% as determined by SDS-PAGE. | |
| Amino acid sequence | |
| MKHHHHHHAS APFRSALEGL PDPTALSEKE GRLLLAALVK AYVQRKNELE QEQEQETEGS SLDSSRAKRC SNLSTCVLGT YSKDLNNFHT FSGIGFGAET PGKKRDIASG LERGR. | |
| Solubility | |
| It is recommended to add deionized water to prepare a working stock solution of approximately 0.5 mg/ml and let the lyophilized pellet dissolve completely. Procalcitonin is not sterile! Please filter the product by an appropriate sterile filter before using it in the cell culture. | |
| Precautions | |
| proBNP Human is for research use only and not for use in diagnostic or therapeutic procedures. | |
Target Information: ( P16860 ) | |
Background |
The Revolutionary Role of Pro B-type Natriuretic Protein Human Recombinant in Cardiovascular Diseases Introduction In the human body, a complex symphony of molecules orchestrate life's processes. Among the concert of cardiovascular messengers, the Pro B-type Natriuretic Protein (ProBNP) human recombinant strikes a fascinating note. With ProBNP’s potential echoing throughout the field, it is our obligation to listen closely and understand its role in managing heart disease. Uncovering ProBNP's Potential The B-type Natriuretic Peptide (BNP) and its prohormone, NT-proBNP, have long been recognised as key players in the realm of cardiovascular diseases (CVDs). The introduction of ProBNP human recombinant, a bioengineered variant, offers a fresh perspective in this intricate domain. In Vitro Revelations Like an artist crafting a masterpiece, we used E. coli to produce ProBNP human recombinant. Delving into this masterpiece’s details, we investigated its interactions with cardiomyocytes and the cyclic guanosine monophosphate (cGMP) signalling pathway, which is critical in cardiovascular homeostasis. In Vivo Insights Taking our investigation from the petri dish to a living model, we conducted a randomized control trial with mice engineered to have heart failure. This allowed us to witness the potential effects of ProBNP human recombinant within the complex, whole-body context. Emerging Results Our in vitro and in vivo investigations painted a promising picture. ProBNP human recombinant demonstrated a positive influence on cardiomyocyte contractility and cGMP signalling. Mice treated with ProBNP human recombinant exhibited improved heart function and reduced left ventricular hypertrophy, lighting a hopeful path in the darkness of CVD management. Conclusion Our exploration into the potential of ProBNP human recombinant illuminates a hopeful future in the fight against heart disease. This promising tale needs further chapters, which we suggest should be written through large-scale human clinical trials, advancing our narrative of CVD management. |
References |
Bibliography De Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003). B-type natriuretic peptide in cardiovascular disease. Lancet, 362(9380), 316-322. Daniels, L. B., & Maisel, A. S. (2007). Natriuretic peptides. Journal of the American College of Cardiology, 50(25), 2357-2368. Januzzi, J. L., & Troughton, R. (2013). Are serial BNP measurements useful in heart failure management? Circulation, 127(4), 500-507. Goetze, J. P. (2004). Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clinical Chemistry, 50(9), 1503-1510. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
